FY2024 EPS Estimates for BioNTech Decreased by Analyst

BioNTech SE (NASDAQ:BNTX) – Investment analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($3.79) per share for the year, down from their prior forecast of ($1.84). The consensus estimate for BioNTech’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for BioNTech’s Q4 2024 earnings at $0.42 EPS, Q1 2025 earnings at ($1.81) EPS, Q2 2025 earnings at ($2.30) EPS, Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $1.85 EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($2.04) EPS and FY2028 earnings at ($1.09) EPS.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the business posted $0.73 earnings per share. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year.

A number of other research firms have also commented on BNTX. UBS Group raised their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 target price on shares of BioNTech in a research note on Thursday. Bank of America boosted their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.54.

BioNTech Stock Down 3.7 %

BioNTech stock opened at $99.72 on Monday. The company’s 50-day moving average price is $113.54 and its two-hundred day moving average price is $97.29. The stock has a market cap of $23.91 billion, a price-to-earnings ratio of -47.49 and a beta of 0.26. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Institutional Trading of BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of the business. Candriam S.C.A. lifted its stake in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of BioNTech by 63.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after purchasing an additional 7,340 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the period. Discovery Capital Management LLC CT acquired a new position in BioNTech in the 2nd quarter valued at approximately $2,467,000. Finally, Deerfield Management Company L.P. Series C increased its stake in BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after buying an additional 24,426 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.